Benzinga -
- Genprex Inc (NASDAQ: GNPX) announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).
- The studies used the company's non-viral Oncoprex Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (NSCLC) humanized mouse models.
- Data were presented at the 2023 American Association of Cancer Research (AACR) annual meeting.
- In the study, humanized mice were treated with NPRL2 gene therapy, immunotherapy Merck's (NYSE: MRK) pembrolizumab (Keytruda), or the combination.
- An antitumor effect was mediated by NPRL2 treatment, whereas pembrolizumab was ineffective.
- A significant antitumor effect was also found in non-humanized NSG mice. However, the antitumor effect was greater in humanized mice, suggesting that the immune response played a role in inducing antitumor activity.
- The study data suggest that NPRL2 gene therapy induces antitumor activity on KRAS/STK11 mutant anti-PD1 resistant tumors through DC-mediated antigen presentation and cytotoxic immune cell activation.
- Price Action: GNPX shares are up 3.15% at $0.98 on the last check Wednesday.